Asundexian for Secondary Stroke Prevention

So some-- First, a background.

Stroke remains a major cause of death and disability worldwide.

Despite current secondary prevention strategies, approximately five percent of patients experience a recurrent stroke within one year.

Current antiplatelet therapies reduce risk but do not eliminate it, and prolonged dual antiplatelet therapy could potentially increase the risk of bleeding for our patients.

And because residual thrombotic risk remains despite guideline-directed therapy, there is an interest in identifying safer antithrombotic approaches that can further reduce recurrent ischemic events without sustainable increased bleeding.

And so this what-- is what led us to potentially looking at these medications.

So prior studies of these medications.

So we have the Pacific Stroke Study.

And so this study, what we're gonna be looking at, is called the Os-Oceanic Stroke Study.

But first, I really just wanted to talk about the established rationale behind the trial and why this trial was created.

And so factor-- with factor XI or XI has become an attractive anticoagulant target because it appears to contribute to some sort of the pathogenic thrombosis, thrombosis while playing a relative limited role in normal hemostasis.

And so really the hope is to find a factor XI or XI that can reduce thrombotic events while causing less bleeding than our traditional anticoagulants.

So there's been several studies looking at this in hopes to find a new medication that we could, uh, bring to market that could potentially reduce our bleeding risk while also preventing clots.